FindTrial
Sign In

Efficiency of dolutegravir in treatment of HIV infected children

Efficacy of dolutegravir based antiretroviral regimen in HIV positive children - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/08/072710
Enrollment
75
Registered
2024-08-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Department of Paediatrics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients substituted to Dolutegravir based regimen from older treatment regimens. Newly diagnosed HIV positive children started on DTG regimen.

Exclusion criteria

Exclusion criteria: Coinfection with Tuberculosis, Hepatitis B and Hepatitis C. Patients with chronic liver disease and auto immune diseases.

Design outcomes

Primary

MeasureTime frame
Proportion of patients having viral suppression after 6 months of treatment with Dolutegravir based regimen.Timepoint: 6 months—

Secondary

MeasureTime frame
1. Proportion of patients having adverse events (if any) following treatment with dolutegravir based regimen and grading of severity of adverse events. 2. Proportion of patients adherent to treatment with Dolutegravir based regimen.Timepoint: 6 months—

Countries

India

Contacts

Public ContactDeepak kumar

Maulana Azad Medical College

deepakk70@gmail.com9211377848

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 9, 2026